About
Targeted Cell-Based Immunotherapy
Areas of Focus
Categories
Biologics & BiopharmaceuticalMidwest
Clinical Trials (4)
View allTotal Trials
4
As Lead Sponsor
4
As Collaborator
0
Total Enrollment
146
By Phase
PHASE2/PHASE3: 1PHASE2: 1PHASE1/PHASE2: 1
By Status
COMPLETED: 2ACTIVE_NOT_RECRUITING: 1NO_LONGER_AVAILABLE: 1
Clinical Trials Pipeline3 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
Today
Hover over trial bars to see details
Recent Trials
NCT05685004Lead Sponsor
Study of Neoantigen-specific Adoptive T Cell Therapy for Newly Diagnosed MGMT Negative Glioblastoma Multiforme (GBM)
PHASE2/PHASE3Active, not recruiting
120 participants
Started: Sep 15, 2023 · Completed: Mar 31, 2027
NCT01290692Lead Sponsor
Study To Test the Safety and Efficacy of TVI-Brain-1 As A Treatment for Recurrent Grade IV Glioma
PHASE2Completed
14 participants
Started: Jun 30, 2011 · Completed: Feb 28, 2014
NCT01081223Lead Sponsor
Phase I/II Study To Test The Safety and Efficacy of TVI-Brain-1 As A Treatment For Recurrent Grade IV Glioma
PHASE1/PHASE2Completed
12 participants
Started: Apr 30, 2010 · Completed: Mar 31, 2011
NCT05936216Lead Sponsor
TVI-Brain-1 in Expanded Access Patient
N/ANO_LONGER_AVAILABLE
Locations (1)
Headquarters
Olathe, KS, United States
Map
Loading map...